Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS)
Diseases of the Nervous System
What is the purpose of this trial?
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS. Ocrelizumab will be administered as two intravenous (IV) infusions of 300 milligrams (mg) on Days 1 and 15. Subsequent doses will be given as single 600-mg infusions. Participants will be randomized to receive lumbar puncture (LP) post-treatment at Week 12, 24, or 52.
- Ages18 years - 55 years
- Trial withGenentech Foundation for Biomedical Sciences
- Start Date06/28/2016
- End Date09/29/2018
- Last Updated02/22/2018
- Study HIC#1602017292